Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...

The active ingredient in Nucala is mepolizumab. (An active ingredient is what makes a drug work.) Nucala is given as an injection under your skin. A healthcare professional may give you these ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

Nucala (mepolizumab) is a prescription drug used to treat a certain kind of asthma and some other immune-related conditions. The drug is typically given once every 4 weeks as an injection under ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...